Navigating TKI Toxicities: Expert Perspectives and Clinical Distinctions
An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, including hypertension (HTN), fatigue, and diarrhea. For third-line tivozanib, tolerability and common toxicities (eg, Palmar-Plantar Erythrodysesthesia (PPE), HTN) are considered. AE incidence, discontinuation rates, and drug interactions guide treatment choices. Managing toxicities involves prevention, monitoring, and mitigation strategies, with dose modifications tailored based on severity and combination regimens. Community oncologists are advised on proactive AE management to optimize outcomes.
Video content above is prompted by the following:
- How do you counsel patients regarding the risk of AEs with single-agent TKIs? And with lenvatinib/everolimus? What do you view as clinically relevant distinctions in their safety profiles?
- Please share your perspectives on the tolerability of tivozanib vs other options you would strongly consider as third-line therapy for a patient like this.
- Most common toxicities
- Incidence of grade 3 or greater AEs, discontinuations
- Drug-drug interactions
- What toxicities are most concerning to you? Which do you find most challenging to manage (eg, HTN, fatigue, PPE/hand-foot skin reaction (HFSR) diarrhea)?
- What advice can you offer to community oncologists with respect to management of TKI-associated AEs?
- How do you prevent, monitor, mitigate, and manage TKI-associated toxicities?
- How do you decide which drug to modify when using a combination regimen?
Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC
March 11th 2025During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
